Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTN | P21246 | 1/20 | 0.40 |
| ▸ | MDK | P21741 | 1/20 | 0.40 |
| ▸ | BDNF | P23560 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
| ▸ | HK1 | P19367 | 1/20 | 0.37 |
| ▸ | HK2 | P52789 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689074 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15966272 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL30089326 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL20474503 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15966248 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL23631128 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15965653 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| Phosphoric Acid SCHEMBL27756060 | 0.95 | AMDHD2 (0.46) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL20415021 | 0.88 | BDNF (0.38) | MAPK1ALDH1A1THRBPTNMDK | |
| SCHEMBL16566075 | 0.87 | ALDH1A1 (0.40) | MAPK1ALDH1A1THRBPTNMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| CN-119375384-A | Method for in-vitro detection of mucopolysaccharide and pompe disease related biomarker | 浙江博圣生物技术股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-117683830-A | Anticoagulant heparin-chondroitin chimeric sugar molecule and preparation method and application thereof | 山东大学 | 2024-03-12 | — | — | CN | claimed |
| WO-2024032575-A1 | HEPARIN DODECASACCHARIDE CONTAINING DOUBLE ANTITHROMBIN BINDING SEQUENCE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 山东大学 | 2024-02-15 | — | — | WO | claimed |
| US-20240041943-A1 | METHOD OF ISOLATION, PURIFICATION, AND CHARACTERIZATION OF HEPARIN-LIKE SUBSTANCES FROM SNAIL MUCUS (ACHATINA FULICA) AND ITS USES | ADEN INTERNATIONAL CO.,LTD. (TH) | 2024-02-08 | — | — | US | claimed |
| CN-113666980-B | High-selectivity Xa factor inhibitor heparin heptasaccharide and preparation method and application thereof | 山东大学 | 2023-12-26 | — | — | CN | claimed |
| CN-117064909-A | Oligosaccharide mixture derived from heparan caprae seu ovis and preparation method and application thereof | 苏州融析生物科技有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4274589-A1 | A NOVEL METHOD OF ISOLATION, PURIFICATION, AND CHARACTERIZATION OF HEPARIN-LIKE SUBSTANCES FROM SNAIL MUCUS (ACHATINA FULICA) AND ITS USES | Aden International Co., Ltd. (TH) | 2023-11-15 | — | — | EP | claimed |
| CN-113583151-B | Heparin molecules containing AT binding sequences and continuous 2-O-glucuronic acid residues, and preparation method and application thereof | 山东大学 | 2023-06-20 | — | — | CN | claimed |
| CN-115417937-B | Heparin dodecasaccharide containing double antithrombin binding sequence and preparation method and application thereof | 山东大学 | 2023-06-06 | — | — | CN | claimed |
| US-11624736-B1 | Method for identifying whether porcine heparin is adulterated with heparin from ruminants | SHANDONG UNIVERSITY (CN) | 2023-04-11 | — | — | US | claimed |
| WO-2023280235-A1 | HEPARIN MOLECULE CONTAINING AT BINDING SEQUENCE AND CONTINUOUS 2-O-GLUCURONIC ACID RESIDUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东大学 | 2023-01-12 | — | — | WO | claimed |
| US-20220404379-A1 | SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES | SHANDONG UNIVERSITY (CN) | 2022-12-22 | — | — | US | claimed |
| CN-115417937-A | Heparin decabiose containing double-antithrombin binding sequence and preparation method and application thereof | 山东大学 | 2022-12-02 | — | — | CN | claimed |
| CN-113393904-B | Method and system for detecting low-molecular heparin sugar chain sequence and sequencing kit | 山东大学 | 2022-10-18 | — | — | CN | claimed |
| WO-2022150018-A1 | A NOVEL METHOD OF ISOLATION, PURIFICATION, AND CHARACTERIZATION OF HEPARIN-LIKE SUBSTANCES FROM SNAIL MUCUS (ACHATINA FULICA) AND ITS USES | ADEN INTERNATIONAL CO.,LTD. (TH) | 2022-07-14 | — | — | WO | claimed |
| CN-114703242-A | Double-enzyme co-immobilization synthesis method of uridine diphosphate-N-acetylglucosamine and derivatives thereof | 山东大学 | 2022-07-05 | — | — | CN | claimed |
| EP-4018200-A1 | METHODS, KITS AND COMPOSITIONS FOR DIAGNOSING AND TREATING RENAL DISEASE | Hill's Pet Nutrition, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021126158-A1 | METHODS, KITS AND COMPOSITIONS FOR DIAGNOSING AND TREATING RENAL DISEASE | HILL'S PET NUTRITION, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| WO-2026041790-A1 | DI(DISPIRODIAZATRIPIPERAZINE)-TRIAZINE DERIVATIVES AND THEIR USE FOR TREATMENT OR PREVENTION OF VIRAL INFECTIONS | Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts (DE) | 2026-02-26 | — | — | WO | disclosed |
| US-12539311-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4656735-A1 | INIBHITION OF REVERSE TRANSCRIPTION DERIVED FROM RIBOSOMAL RNA | Toyobo Co., Ltd. (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20250281523-A1 | SULFATED GLYCOSAMINOGLYCAN COMPOUNDS, METHODS, AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250255909-A1 | PREVOTELLA COPRI FORMULATIONS AND METHODS OF USE | INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH (BD) | 2025-08-14 | — | — | US | disclosed |
| US-20250237650-A1 | GLYCOSAMINOGLYCAN ARTICLES AND METHODS RELATING THERETO | NATIONAL SCIENCE FOUNDATION | 2025-07-24 | — | — | US | disclosed |
| EP-4578462-A2 | DERMAL FILLER COMPOSITIONS | ALLERGAN Industrie, SAS (FR) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025122575-A1 | TREATMENT FOR DISEASE MODIFICATION | EXTHERA MEDICAL CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2025-06-12 | — | — | US | disclosed |
| CN-116769069-B | Small-molecule non-anticoagulant heparin, preparation method thereof, and pharmaceutical composition and application thereof | 苏州融析生物科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119375384-A | Method for in-vitro detection of mucopolysaccharide and pompe disease related biomarker | 浙江博圣生物技术股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-12196743-B2 | Method for analyzing glycosaminoglycan | SHIMADZU CORPORATION (JP) | 2025-01-14 | — | — | US | disclosed |
| US-12188058-B2 | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240366853-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | EXTHERA MEDICAL CORPORATION (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118852492-A | Fucosylated heparan sulfate and preparation method and application thereof | 山东大学 | 2024-10-29 | — | — | CN | disclosed |
| EP-4448734-A1 | PRODUCTION OF ALPHA-1,3-FUCOSYLATED COMPOUNDS | Inbiose N.V. (BE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448781-A1 | PRODUCTION OF ALPHA-1,4-FUCOSYLATED COMPOUNDS | Inbiose N.V. (BE) | 2024-10-23 | — | — | EP | disclosed |
| US-20240343826-A1 | Compositions and Methods for Targeting Cancer Stem Cells | SEAGEN INC. (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240342072-A1 | DERMAL FILLER COMPOSITIONS | ALLERGAN INC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240343834-A1 | Compositions and Methods for Targeting Cancer Stem Cells | SEAGEN INC. (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240342279-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2024-10-17 | — | — | US | disclosed |
| US-12090261-B2 | Method for modulating endothelial glycocalyx structure | EXTHERA MEDICAL CORPORATION (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240301092-A1 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | TEGA THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| EP-4426750-A2 | METHODS FOR THE CHEMOENZYMATIC SYNTHESIS OF LOW MOLECULAR WEIGHT HEPARIN FROM LOW MOLECULAR WEIGHT HEPAROSAN | Rensselaer Polytechnic Institute (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4413994-A2 | MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN LYSOSOMAL SULFATASE ENZYMES AND USES THEREOF | BioMarin Pharmaceutical Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240245718-A1 | MEDIUM MOLECULAR WEIGHT HEPARIN FOR USE IN THE TREATMENT OF ENDOTHELIOPATHY | GLYCOS BIOMEDICAL LTD (GB) | 2024-07-25 | — | — | US | disclosed |
| CN-118308338-A | PL35 family chondroitin sulfate lyase and encoding gene and application thereof | 山东第二医科大学 | 2024-07-09 | — | — | CN | disclosed |
| EP-3219795-B1 | MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN LYSOSOMAL SULFATASE ENZYMES AND USES THEREOF | BIOMARIN PHARM INC (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117683830-A | Anticoagulant heparin-chondroitin chimeric sugar molecule and preparation method and application thereof | 山东大学 | 2024-03-12 | — | — | CN | disclosed |
| US-20240066048-A1 | SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-29 | — | — | US | disclosed |
| CN-114763570-B | Construction and application of sulfonated modification system for preparing heparin with different molecular weights | 江南大学 | 2024-02-27 | — | — | CN | disclosed |
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2024032575-A1 | HEPARIN DODECASACCHARIDE CONTAINING DOUBLE ANTITHROMBIN BINDING SEQUENCE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 山东大学 | 2024-02-15 | — | — | WO | disclosed |
| US-20240041943-A1 | METHOD OF ISOLATION, PURIFICATION, AND CHARACTERIZATION OF HEPARIN-LIKE SUBSTANCES FROM SNAIL MUCUS (ACHATINA FULICA) AND ITS USES | ADEN INTERNATIONAL CO.,LTD. (TH) | 2024-02-08 | — | — | US | disclosed |
| US-20240009306-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20240002422-A1 | Glycan Analysis and Profiling | SEAGEN INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20240002537-A1 | Compositions and Methods for Targeting Cancer Stem Cells | SEAGEN INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20240000962-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20240003889-A1 | Compositions and Methods for Targeting Cancer Stem Cells | SEAGEN INC. (US) | 2024-01-04 | — | — | US | disclosed |
| CN-117285660-A | Novel heparan sulfate and preparation method and application thereof | 山东大学 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023229537-A2 | RECOMBINANT HEPARAN SULFATES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-11-30 | — | — | WO | disclosed |
| CN-117064909-A | Oligosaccharide mixture derived from heparan caprae seu ovis and preparation method and application thereof | 苏州融析生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4274589-A1 | A NOVEL METHOD OF ISOLATION, PURIFICATION, AND CHARACTERIZATION OF HEPARIN-LIKE SUBSTANCES FROM SNAIL MUCUS (ACHATINA FULICA) AND ITS USES | Aden International Co., Ltd. (TH) | 2023-11-15 | — | — | EP | disclosed |
| US-20230331868-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230310700-A1 | DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS | ALLERGAN IND SAS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-20230312747-A1 | Compositions and Methods for Treating Cancer | SEAGEN INC. (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116769069-A | Small-molecule non-anticoagulant heparin, preparation method thereof, and pharmaceutical composition and application thereof | 苏州融析生物科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023157899-A1 | RECOMBINANT HEPARIN-LIKE SUBSTANCE AND METHOD FOR PRODUCING SAME | 国立大学法人九州大学 | 2023-08-24 | — | — | WO | disclosed |
| EP-4213884-A1 | MOLECULES WITH SOLUBILITY TAG AND RELATED METHODS | Merck Patent GmbH (DE) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023110994-A1 | PRODUCTION OF ALPHA-1,4-FUCOSYLATED COMPOUNDS | INBIOSE N.V. (BE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023110995-A1 | PRODUCTION OF ALPHA-1,3-FUCOSYLATED COMPOUNDS | INBIOSE N.V. (BE) | 2023-06-22 | — | — | WO | disclosed |
| CN-115417937-B | Heparin dodecasaccharide containing double antithrombin binding sequence and preparation method and application thereof | 山东大学 | 2023-06-06 | — | — | CN | disclosed |
| EP-4183806-A2 | GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE | Seagen Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023086885-A1 | GLYCOSAMINOGLYCAN ARTICLES AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230151400-A1 | BIOSYNTHETIC HEPARIN | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2023-05-18 | — | — | US | disclosed |
| EP-3510147-B1 | BIOSYNTHETIC HEPARIN | RENSSELAER POLYTECH INST (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230142697-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023081336-A2 | METHODS FOR THE CHEMOENZYMATIC SYNTHESIS OF LOW MOLECULAR WEIGHT HEPARIN FROM LOW MOLECULAR WEIGHT HEPAROSAN | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-114763518-B | Construction and application of yeast engineering bacteria for producing heparin by fermentation | 江南大学 | 2023-04-28 | — | — | CN | disclosed |
| US-20230122509-A1 | METHOD FOR ANALYZING GLYCOSAMINOGLYCAN | SHIMADZU CORPORATION (JP) | 2023-04-20 | — | — | US | disclosed |
| US-11624736-B1 | Method for identifying whether porcine heparin is adulterated with heparin from ruminants | SHANDONG UNIVERSITY (CN) | 2023-04-11 | — | — | US | disclosed |
| US-11624736-B1 | Method for identifying whether porcine heparin is adulterated with heparin from ruminants | SHANDONG UNIVERSITY (CN) | 2023-04-11 | — | — | US | disclosed |
| WO-2023036103-A1 | CONSTRUCTION OF SULFONATION MODIFICATION SYSTEM FOR PREPARATION OF HEPARINS HAVING DIFFERENT MOLECULAR WEIGHTS, AND APPLICATION THEREOF | 江南大学 | 2023-03-16 | — | — | WO | disclosed |
| WO-2023035584-A1 | CONSTRUCTION AND APPLICATION OF YEAST ENGINEERING BACTERIA FOR FERMENTATIVE PRODUCTION OF HEPARIN | 江南大学 | 2023-03-16 | — | — | WO | disclosed |
| EP-3232193-B1 | DIAGNOSIS OF MPS I DISORDERS BY MEASURING NON-REDUCING ENDS OF GAGS AFTER ENZYMATIC DIGEST | BIOMARIN PHARM INC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11591628-B2 | Biosynthetic heparin | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2023-02-28 | — | — | US | disclosed |
| US-RE49435-E1 | Glycan-interacting compounds and methods of use | SEAGEN INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230029085-A1 | Compositions and Methods for Targeting Cancer Stem Cells | SEAGEN INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230022411-A1 | Compositions and Methods for Targeting Cancer Stem Cells | SEAGEN INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2023280235-A1 | HEPARIN MOLECULE CONTAINING AT BINDING SEQUENCE AND CONTINUOUS 2-O-GLUCURONIC ACID RESIDUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东大学 | 2023-01-12 | — | — | WO | disclosed |
| US-20230001007-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2023278631-A1 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | TEGA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-3218005-B1 | GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE | SEAGEN INC (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220404379-A1 | SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES | SHANDONG UNIVERSITY (CN) | 2022-12-22 | — | — | US | disclosed |
| CN-115417937-A | Heparin decabiose containing double-antithrombin binding sequence and preparation method and application thereof | 山东大学 | 2022-12-02 | — | — | CN | disclosed |
| US-20220380489-A1 | METHOD FOR PRODUCING HEPARIN-LIKE SUBSTANCE, RECOMBINANT CELL, AND METHOD FOR PRODUCING THE SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2022-12-01 | — | — | US | disclosed |
| CN-113393904-B | Method and system for detecting low-molecular heparin sugar chain sequence and sequencing kit | 山东大学 | 2022-10-18 | — | — | CN | disclosed |
| US-11458211-B2 | Gene therapy | THE UNIVERSITY OF MANCHESTER (GB) | 2022-10-04 | — | — | US | disclosed |
| US-11441131-B2 | Heparosan synthases and use thereof for saccharide synthesis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-13 | — | — | US | disclosed |
| CN-114264741-B | Method for identifying whether pig-derived heparin is doped with ruminant heparin | 山东大学 | 2022-08-19 | — | — | CN | disclosed |
| US-20220259323-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-4039814-A1 | METHOD FOR PRODUCING HEPARIN-LIKE SUBSTANCE, RECOMBINANT CELLS AND METHOD FOR PRODUCING SAME | Kyushu University, National University Corporation (JP) | 2022-08-10 | — | — | EP | disclosed |
| US-11401330-B2 | Glycan-interacting compounds and methods of use | SEAGEN INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-114763518-A | Construction and application of yeast engineering bacteria for producing heparin by fermentation | 江南大学 | 2022-07-19 | — | — | CN | disclosed |
| CN-114763570-A | Construction and application of sulfonation modification system for preparing heparins with different molecular weights | 江南大学 | 2022-07-19 | — | — | CN | disclosed |
| WO-2022150018-A1 | A NOVEL METHOD OF ISOLATION, PURIFICATION, AND CHARACTERIZATION OF HEPARIN-LIKE SUBSTANCES FROM SNAIL MUCUS (ACHATINA FULICA) AND ITS USES | ADEN INTERNATIONAL CO.,LTD. (TH) | 2022-07-14 | — | — | WO | disclosed |
| CN-114703242-A | Double-enzyme co-immobilization synthesis method of uridine diphosphate-N-acetylglucosamine and derivatives thereof | 山东大学 | 2022-07-05 | — | — | CN | disclosed |
| WO-2022124944-A1 | DI(DIAZONIADISPIRO[5.2.5.2]HEXADECAN)-5-NITROPYRIMIDINES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | FEDERAL RESEARCH CENTRE “FUNDAMENTALS OF BIOTECHNOLOGY” OF THE RUSSIAN ACADEMY OF SCIENCES (RU) | 2022-06-16 | — | — | WO | disclosed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| CN-114264741-A | Method for identifying whether pig-derived heparin is doped with ruminant heparin | 山东大学 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022058548-A1 | MOLECULES WITH SOLUBILITY TAG AND RELATED METHODS | MERCK PATENT GMBH (DE) | 2022-03-24 | — | — | WO | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220023186-A1 | DERMAL FILLER COMPOSITIONS | ALLERGAN INDUSTRIE, SAS (FR) | 2022-01-27 | — | — | US | disclosed |
| US-20200271601-A1 | Method for the Analysis of Glycosaminoglycans, and Their Derivatives and Salts by Nuclear Magnetic Resonance | LABORATORIOS FARMACÉUTICOS ROVI, S.A. (ES) | 2020-08-27 | — | — | US | disclosed |
| US-20200271601-A1 | Method for the Analysis of Glycosaminoglycans, and Their Derivatives and Salts by Nuclear Magnetic Resonance | LABORATORIOS FARMACÉUTICOS ROVI, S.A. (ES) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281523-A1 | SULFATED GLYCOSAMINOGLYCAN COMPOUNDS, METHODS, AND USES THEREOF | HPSE, CSGALNACT1, DDOST | MAPK1 2803/4885AMDHD2 57/4885ALDH1A1 1545/4885 |
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | HPSE, STS, SULT1A1 | MAPK1 2401/4885AMDHD2 97/4885ALDH1A1 1437/4885 |
| US-20240342072-A1 | DERMAL FILLER COMPOSITIONS | CD44, HACD3, CUTA | MAPK1 4233/4885AMDHD2 58/4885ALDH1A1 822/4885 |
| US-20220023186-A1 | DERMAL FILLER COMPOSITIONS | CD44, HACD3, CUTA | MAPK1 4233/4885AMDHD2 58/4885ALDH1A1 822/4885 |
| US-20240066048-A1 | SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS | HPSE, STS, SULT1A1 | MAPK1 2401/4885AMDHD2 97/4885ALDH1A1 1437/4885 |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | HPSE, CD44, CSGALNACT1 | MAPK1 3351/4885AMDHD2 338/4885ALDH1A1 2195/4885 |
| US-12539311-B2 | Short-acting heparin-based anticoagulant compounds and methods | STS, TPST2, HPSE | MAPK1 2281/4885AMDHD2 39/4885ALDH1A1 1934/4885 |
| US-20240301092-A1 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | MST1, MST1R, HPSE | MAPK1 2047/4885AMDHD2 43/4885ALDH1A1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.